CervoMed (CRVO) 10-Q 10 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 05, 2018
Document Information [Line Items]
Entity Registrant Name	Diffusion Pharmaceuticals Inc.
Entity Central Index Key	1,053,691
Trading Symbol	dffn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		50,526,547
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 16,199,481	$ 8,896,468
Prepaid expenses, deposits and other current assets	890,891	769,946
Total current assets	17,090,372	9,666,414
Property and equipment, net	432,634	460,652
Intangible asset	8,639,000	8,639,000
Goodwill	6,929,258	6,929,258
Other assets	275,714	450,491
Total assets	33,366,978	26,145,815
Current liabilities:
Current portion of convertible debt	550,000	550,000
Accounts payable	419,103	511,956
Accrued expenses and other current liabilities	453,713	1,628,851
Total current liabilities	1,422,816	2,690,807
Deferred income taxes	2,223,678	2,223,678
Other liabilities		1,386
Total liabilities	3,646,494	4,915,871
Commitments and Contingencies (Note 7)
Series A - 13,750,000 shares authorized at both March 31, 2018 and December 31, 2017. No shares and 12,376,329 shares issued at March 31, 2018 and December 31, 2017, respectively. No shares and 8,306,278 outstanding at March 31, 2018 and December 31, 2017, respectively.	0	0
Stockholders’ Equity:
1,000,000,000 shares authorized; 50,526,547 and 14,519,629 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively.	50,526	14,520
Additional paid-in capital	94,538,808	82,770,313
Accumulated deficit	(64,868,850)	(61,554,889)
Total stockholders' equity	29,720,484	21,229,944
Total liabilities, convertible preferred stock and stockholders' equity	$ 33,366,978	$ 26,145,815

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	13,750,000	13,750,000
Preferred stock, shares issued (in shares)	0	12,376,329
Preferred stock, shares outstanding (in shares)	0	8,306,278
Preferred stock, liquidation value	$ 0	$ 16,778,682
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	50,526,547	14,519,629
Common stock, shares outstanding (in shares)	50,526,547	14,519,629

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating expenses:
Research and development	$ 1,825,568	$ 1,007,571
General and administrative	1,497,839	1,553,139
Depreciation	28,018	6,603
Loss from operations	3,351,425	2,567,313
Other expense:
Interest (income) expense, net	(37,464)	55,719
Change in fair value of warrant liabilities		12,919,674
Warrant related expenses		10,225,846
Other financing expenses		2,870,226
Net loss	(3,313,961)	(28,638,778)
Series A cumulative preferred dividends	(85,993)	(58,845)
Deemed dividend related to the make-whole provision for the conversion of Series A preferred stock into common stock	(8,167,895)
Net loss attributable to common stockholders	$ (11,567,849)	$ (28,697,623)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.27)	$ (2.78)
Weighted average shares outstanding, basic and diluted (in shares)	42,122,395	10,337,726

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	8,306,278	14,519,629
Balance at Dec. 31, 2017		$ 14,520	$ 82,770,313	$ (61,554,889)		$ 21,229,944
Conversion of Series A convertible preferred stock to common stock (in shares)	(8,306,278)	8,306,278
Conversion of Series A convertible preferred stock to common stock		$ 8,306	(8,306)
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature (in shares)		11,668,421
Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature		$ 11,668	(11,668)
Issuance of common stock related to accrued dividends (in shares)		1,032,219
Issuance of common stock related to accrued dividends		$ 1,032	1,147,275			1,148,307
Series A cumulative preferred dividends			(85,993)		$ (85,993)	(85,993)
Issuance of common stock and warrants, net of issuance costs (in shares)		15,000,000
Issuance of common stock and warrants, net of issuance costs		$ 15,000	10,402,520			10,417,520
Stock-based compensation expense			324,667			324,667
Net loss				(3,313,961)		(3,313,961)
Balance (in shares) at Mar. 31, 2018		50,526,547
Balance at Mar. 31, 2018		$ 50,526	$ 94,538,808	$ (64,868,850)		$ 29,720,484

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating activities:
Net loss	$ (3,313,961)	$ (28,638,778)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	28,018	6,603
Stock-based compensation expense	324,667	366,383
Warrant related expense, change in fair value, and other financing expenses		26,015,746
Non-cash interest expense	1,356	57,185
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(92,944)	(99,737)
Accounts payable, accrued expenses and other liabilities	(236,420)	(1,123,303)
Net cash used in operating activities	(3,289,284)	(3,415,901)
Cash flows used in investing activities:
Purchases of property and equipment		(6,372)
Net cash used in investing activities		(6,372)
Cash flows provided by financing activities:
Proceeds from the sale of common stock	10,846,062
Proceeds from the sale of Series A convertible preferred stock, net		14,269,095
Payment of offering costs	(253,765)	(187,649)
Net cash provided by financing activities	10,592,297	14,081,446
Net increase in cash and cash equivalents	7,303,013	10,659,173
Cash and cash equivalents at beginning of period	8,896,468	1,552,852
Cash and cash equivalents at end of period	16,199,481	12,212,025
Supplemental disclosure of non-cash financing activities:
Reclassification of accrued dividends related to the issuance of common stock to the Series A convertible preferred stock holders	1,148,307
Reclassification of deferred offering costs upon completion of private placement		180,456
Offering costs in accounts payable and accrued expenses	174,777	178,258
Series A cumulative preferred dividends	(85,993)
Issuance of subscription receivable upon sale of Series A convertible preferred stock		(8,280,935)
Series A Preferred Stock [Member]
Supplemental disclosure of non-cash financing activities:
Series A cumulative preferred dividends	$ (85,993)	$ (58,845)

Note 1 - Organization and Descr

Note 1 - Organization and Description of Business	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization and Description of Business Diffusion Pharmaceuticals Inc. (“Diffusion” or “the Company”, “we” or “us”), a Delaware corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (“TSC”), for use in the many cancer types in which tumor oxygen deprivation (“hypoxia”) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.

Note 2 - Liquidity

Note 2 - Liquidity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Liquidity [Text Block]	2. Liquidity The Company has not No The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third January 22, 2018, 15,000,000 $0.001 15,000,000 1,970,625 $0.80 $10.8 $0.80 five 750,000 $1.00, five 21,006,918 The Company currently does not may March 2, 2018, not 5550 2 $1.00 30 5810 3 180 August 29, 2018, $1.00 10 third may not Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company believes its cash and cash equivalents as of March 31, 2018 June 2019.

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Basis of Presentation and Summary of Significant Accounting Policies The Summary of Significant Accounting Policies included in our Form 10 December 31, 2017, April 2, 2018, not Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X March 31, 2018, three March 31, 2018 2017. three March 31, 2018 not may December 31, 2018. not December 31, 2017 10 April 2, 2018. Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of March 31, 2018 December 31, 2017, $0.6 3 Convertible Debt The Company has convertible debt of $0.6 March 31, 2018 December 31, 2017. 1%, $2.74, June 30, 2018. March 31, 2018, $38,000, Intangible Assets and Goodwill The Company has an intangible asset, RES- 529, $8.6 $6.9 March 31, 2018 December 31, 2017. 529 October 1 no 529 three March 31, 2018 2017. Net Loss Per Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of Common Stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding as of March 31, 2018 2017 March 31, 2018 2017 Convertible debt 214,880 766,351 Convertible preferred stock — 12,376,329 Common stock warrants 31,707,223 14,016,608 Stock options 3,053,797 2,304,132 Unvested restricted stock awards 1,533 7,665 34,977,433 29,471,085 Amounts in the table reflect the Common Stock equivalents of the noted instruments. Recent Accounting Pronouncements In July 2017, 2017 11, Earnings Per Share (Topic 260 ); Distinguishing Liabilities from Equity (Topic 480 ); Derivatives and Hedging (Topic 815 ): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. first second December 15, 2018 not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018,

Note 4 - Other Accrued Expenses

Note 4 - Other Accrued Expenses and Liabilities	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	4. Other Accrued Expenses and Liabilities Other accrued expenses and liabilities consisted of the following: March 31, 2018 December 31, 2017 Accrued interest payable 38,771 37,415 Accrued Series A dividends — 1,062,314 Accrued payroll and payroll related expenses 184,689 312,221 Accrued professional fees 85,235 122,711 Accrued clinical studies expenses 55,210 63,350 Other accrued expenses 89,808 30,840 Total 453,713 1,628,851

Note 5 - Convertible Preferred

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	5. Convertible Preferred Stock, Common Stock and Common Stock Warrants 2018 In January 2018, 15,000,000 15,000,000 $0.80 $10.8 2,250,000 2,250,000 1,970,625 $0.80 In addition, at the closing, the Company issued to designees of the underwriter warrants to purchase up to 750,000 $1.00 five During its evaluation of equity classification for the Common Stock warrants, the Company considered the conditions as prescribed within ASC 815 40, Derivatives and Hedging, Contracts in an Entity’s own Equity 815 40” 815 40 not not 480 not not 815, As a result of the Company's Common Stock offering in January 2018, 21,006,918 8,306,278 1,032,219 11,668,421 $8.2 Common Stock Warrants As of March 31, 2018, Outstanding Range of exercise price per share Expiration dates Common stock warrants issued before 2016 430,721 $20.00 - $49.00 2018 through 2019 Common stock warrants issued in Series A 13,555,887 $2.22 March 2022 Common stock warrants issued in 2018 related to the common stock offering 17,720,625 $0.80 - $1.00 January 2023 31,707,233 During the three March 31, 2018, 17,392 no

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6. Stock-Based Compensation 2015 The Diffusion Pharmaceuticals Inc. 2015 "2015 January 1 4.0% December 31, 580,785 January 1, 2018, may 2015 March 31, 2018, 185,076 2015 The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim condensed consolidated statements of operations for the periods indicated: Three Months Ended March 31, 2018 2017 Research and development 16,372 43,322 General and administrative 308,295 323,061 Total stock-based compensation expense 324,667 366,383 The following table summarizes the activity related to all stock option grants to employees and non-employees for the three March 31, 2018: Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Balance at January 1, 2018 2,555,989 7.32 Granted 500,000 1.18 Expired (2,192 ) 17.10 Outstanding at March 31, 2018 3,053,797 6.30 7.36 Exercisable at March 31, 2018 2,011,881 7.84 6.46 Non-employee Stock Options Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. The Company did not three March 31, 2018. three March 31, 2018 2017 $1,000 $53,000, March 31, 2018, 11,107 $5,000 1.36 Employee Stock Options The weighted average grant date fair value of stock option awards granted to employees was $0.98 three March 31, 2018. three March 31, 2018 2017 $0.3 $0.2 No March 31, 2018, $2.7 4.97 Options granted were valued using the Black-Scholes model and assumptions used to value the options granted during the first three 2018 Expected term (in years) 5.66 Risk-free interest rate 2.3 % Expected volatility 112.7 % Dividend yield — % Restricted Stock Awards As of March 31, 2018, 1,533 three March 31, 2018, 1,533 $3,000. March 31, 2018, $2,000 second 2018.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Office Space Rental The Company leases an office and laboratory facility in Charlottesville, Virginia. Rent expense related to the Company's operating lease was approximately $28,000 $17,000 three March 31, 2018 2017, not March 31, 2018 Rental Commitments 2018 84,608 2019 114,409 2020 116,464 2021 118,519 Thereafter 39,735 Total 473,735 Arrangement with Clinical Research Organization On July 5, 2017, $0.8 three March 31, 2018. March 31, 2018, $0.5 2018. Legal Proceedings On August 7, 2014, Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH No. BC553996 December 30, 2014, April 1, 2015, April 14, 2015, January 8, 2016, No may

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”), and with the instructions to Form 10 10 X March 31, 2018, three March 31, 2018 2017. three March 31, 2018 not may December 31, 2018. not December 31, 2017 10 April 2, 2018.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of March 31, 2018 December 31, 2017, $0.6 3
Debt, Policy [Policy Text Block]	Convertible Debt The Company has convertible debt of $0.6 March 31, 2018 December 31, 2017. 1%, $2.74, June 30, 2018. March 31, 2018, $38,000,
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill The Company has an intangible asset, RES- 529, $8.6 $6.9 March 31, 2018 December 31, 2017. 529 October 1 no 529 three March 31, 2018 2017.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of Common Stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of Common Stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding as of March 31, 2018 2017 March 31, 2018 2017 Convertible debt 214,880 766,351 Convertible preferred stock — 12,376,329 Common stock warrants 31,707,223 14,016,608 Stock options 3,053,797 2,304,132 Unvested restricted stock awards 1,533 7,665 34,977,433 29,471,085 Amounts in the table reflect the Common Stock equivalents of the noted instruments.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In July 2017, 2017 11, Earnings Per Share (Topic 260 ); Distinguishing Liabilities from Equity (Topic 480 ); Derivatives and Hedging (Topic 815 ): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. first second December 15, 2018 not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018,

Note 3 - Basis of Presentatio15

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2018 2017 Convertible debt 214,880 766,351 Convertible preferred stock — 12,376,329 Common stock warrants 31,707,223 14,016,608 Stock options 3,053,797 2,304,132 Unvested restricted stock awards 1,533 7,665 34,977,433 29,471,085

Note 4 - Other Accrued Expens16

Note 4 - Other Accrued Expenses and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Other Current Liabilities [Table Text Block]	March 31, 2018 December 31, 2017 Accrued interest payable 38,771 37,415 Accrued Series A dividends — 1,062,314 Accrued payroll and payroll related expenses 184,689 312,221 Accrued professional fees 85,235 122,711 Accrued clinical studies expenses 55,210 63,350 Other accrued expenses 89,808 30,840 Total 453,713 1,628,851

Note 5 - Convertible Preferre17

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block]	Outstanding Range of exercise price per share Expiration dates Common stock warrants issued before 2016 430,721 $20.00 - $49.00 2018 through 2019 Common stock warrants issued in Series A 13,555,887 $2.22 March 2022 Common stock warrants issued in 2018 related to the common stock offering 17,720,625 $0.80 - $1.00 January 2023 31,707,233

Note 6 - Stock-based Compensa18

Note 6 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended March 31, 2018 2017 Research and development 16,372 43,322 General and administrative 308,295 323,061 Total stock-based compensation expense 324,667 366,383
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Balance at January 1, 2018 2,555,989 7.32 Granted 500,000 1.18 Expired (2,192 ) 17.10 Outstanding at March 31, 2018 3,053,797 6.30 7.36 Exercisable at March 31, 2018 2,011,881 7.84 6.46
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected term (in years) 5.66 Risk-free interest rate 2.3 % Expected volatility 112.7 % Dividend yield — %

Note 7 - Commitments and Cont19

Note 7 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Rental Commitments 2018 84,608 2019 114,409 2020 116,464 2021 118,519 Thereafter 39,735 Total 473,735

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Jan. 22, 2018	Jan. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Conversion From Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued	21,006,918	21,006,918
Warrants Issued in Connection with the January 2018 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,000,000	15,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80	$ 0.80
Class of Warrant or Right, Term	5 years
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Additional Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.80
Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Underwriter Warrants [Member] | H.C Wainwright & Co., LLC [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Class of Warrant or Right, Term	5 years
Underwriter Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	750,000	750,000
Class of Warrant or Right, Term		5 years
January 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	15,000,000	15,000,000
Share Price	$ 0.80
Proceeds from Issuance or Sale of Equity, Total	$ 10.8	$ 10.8
January 2018 Offering [Member] | Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,970,625

Note 3 - Basis of Presentatio21

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Goodwill, Ending Balance	$ 6,929,258		$ 6,929,258
Impairment of Intangible Assets (Excluding Goodwill), Total	0	$ 0
Goodwill, Impairment Loss	0	$ 0
RES-529 [Member]
Intangible Assets, Net (Excluding Goodwill), Total	8,600,000
Convertible Note, Series B [Member]
Convertible Debt, Total	$ 600,000		600,000
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Debt Instrument, Convertible, Conversion Price	$ 2.74
Convertible Note, Series B [Member] | Accrued Expenses and Other Current Liabilities [Member]
Interest Payable	$ 38,000
Fair Value, Inputs, Level 3 [Member] | Convertible Note, Series B [Member]
Convertible Debt, Fair Value Disclosures	$ 600,000		$ 600,000

Note 3 - Basis of Presentatio22

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Anti-dilutive securities (in shares)	34,977,433	29,471,085
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)	214,880	766,351
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities (in shares)		12,376,329
Warrant [Member]
Anti-dilutive securities (in shares)	31,707,223	14,016,608
Employee Stock Option [Member]
Anti-dilutive securities (in shares)	3,053,797	2,304,132
Restricted Stock [Member]
Anti-dilutive securities (in shares)	1,533	7,665

Note 4 - Other Accrued Expens23

Note 4 - Other Accrued Expenses and Liabilities - Summary of Accrued Expenses (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Accrued interest payable	$ 38,771	$ 37,415
Accrued Series A dividends		1,062,314
Accrued payroll and payroll related expenses	184,689	312,221
Accrued professional fees	85,235	122,711
Accrued clinical studies expenses	55,210	63,350
Other accrued expenses	89,808	30,840
Total	$ 453,713	$ 1,628,851

Note 5 - Convertible Preferre24

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants (Details Textual) - USD ($)	Jan. 22, 2018	Jan. 31, 2018	Mar. 31, 2018	Mar. 31, 2017
Stock Issued During Period, Shares, Conversion of Convertible Securities		8,306,278
Common Stock Dividends, Shares		1,032,219
Stock Issued During Period, Shares, Make-whole Adjustment		11,668,421
Dividends, Make-whole Adjustment		$ 8,200,000	$ 8,167,895
Class of Warrant or Right, Exercised			0
Warrant [Member]
Class of Warrant or Rights, Expired			17,392
Conversion From Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued	21,006,918	21,006,918
Warrants Issued in Connection with the January 2018 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	15,000,000	15,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80	$ 0.80
Class of Warrant or Right, Term	5 years
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Option Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,250,000
Additional Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Granted		1,970,625
Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1
Underwriter Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	750,000	750,000
Class of Warrant or Right, Term		5 years
January 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	15,000,000	15,000,000
Proceeds from Issuance or Sale of Equity, Total	$ 10,800,000	$ 10,800,000
Stock Issued During Period, Shares, Issued for Services		2,250,000
January 2018 Offering [Member] | Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,970,625

Note 5 - Convertible Preferre25

Note 5 - Convertible Preferred Stock, Common Stock and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares	Mar. 31, 2018	Jan. 31, 2018	Jan. 22, 2018
Common stock warrants, outstanding (in shares)	31,707,233
Warrants issued before 2016 [Member]
Common stock warrants, outstanding (in shares)	430,721
Warrants issued before 2016 [Member] | Minimum [Member]
Range of exercise price (in dollars per share)	$ 20
Warrants issued before 2016 [Member] | Maximum [Member]
Range of exercise price (in dollars per share)	$ 49
Series A Convertible Preferred Stock [Member]
Common stock warrants, outstanding (in shares)	13,555,887
Range of exercise price (in dollars per share)	$ 2.22
Warrants Issued in Connection with the January 2018 Offering [Member]
Common stock warrants, outstanding (in shares)	17,720,625
Range of exercise price (in dollars per share)		$ 0.80	$ 0.80
Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member]
Range of exercise price (in dollars per share)	$ 0.80
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member]
Range of exercise price (in dollars per share)	$ 1

Note 6 - Stock-based Compensa26

Note 6 - Stock-based Compensation (Details Textual) - USD ($)	Jan. 01, 2018	Jul. 21, 2016	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0	0
Allocated Share-based Compensation Expense, Total			$ 324,667	$ 366,383
Non-employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 1,000	53,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance			11,107
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 5,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 131 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 300,000	$ 200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 2,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			4 years 354 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 0.98
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance			1,533
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			1,533
Allocated Share-based Compensation Expense, Total			$ 3,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options			$ 2,000
Restorgenex Corporation 2015 Equity Incentive Plan [Member]
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	580,785
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			185,076

Note 6 - Stock-based Compensa27

Note 6 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock-based compensation expense	$ 324,667	$ 366,383
Research and Development Expense [Member]
Stock-based compensation expense	16,372	43,322
General and Administrative Expense [Member]
Stock-based compensation expense	$ 308,295	$ 323,061

Note 6 - Stock-based Compensa28

Note 6 - Stock-based Compensation - Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Options outstanding, number (in shares) | shares	2,555,989
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 7.32
Granted (in shares) | shares	500,000
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.18
Expired (in shares) | shares	(2,192)
Expired, weighted-average exercise price (in dollars per share) | $ / shares	$ 17.10
Options outstanding, number (in shares) | shares	3,053,797
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 6.30
Options outstanding, weighted-average remaining contractual life (Year)	7 years 131 days
Exercisable (in shares) | shares	2,011,881
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares	$ 7.84
Exercisable, weighted-average remaining contractual life (Year)	6 years 167 days

Note 6 - Stock-based Compensa29

Note 6 - Stock-based Compensation - Fair Value Assumptions (Details)	3 Months Ended
	Mar. 31, 2018
Expected term (Year)	5 years 240 days
Risk-free interest rate	2.30%
Expected volatility	112.70%

Note 7 - Commitments and Cont30

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Research and Development Expense, Total	$ 1,825,568	$ 1,007,571
Arrangement With Clinical Research Organization [Member]
Research and Development Expense, Total	800,000
Prepaid Research and Development Expense	500,000
Charlottesville, Virginia [Member] | Building [Member]
Operating Leases, Rent Expense, Net, Total	$ 28,000	$ 17,000

Note 7 - Commitments and Cont31

Note 7 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)	Mar. 31, 2018USD ($)
2,018	$ 84,608
2,019	114,409
2,020	116,464
2,021	118,519
Thereafter	39,735
Total	$ 473,735